Literature DB >> 31663113

Highly oxidized low-density lipoprotein mediates activation of monocytes but does not confer interleukin-1β secretion nor interleukin-15 transpresentation function.

Scott F Sieg1, Douglas A Bazdar1, David Zidar2, Michael Freeman1, Michael M Lederman1, Nicholas T Funderburg3.   

Abstract

Oxidized low-density lipoprotein (LDL) contributes to cardiovascular disease in part by mediating activation and maturation of monocytes and macrophages. Furthermore, co-localization studies using histochemical approaches have implicated a potential role for oxidized LDL as a mediator of interleukin-15 (IL-15) expression in myeloid cells of atherosclerotic plaque. The latter activity could be an important pro-inflammatory mechanism that mediates myeloid cell/T-cell crosstalk. Here, we examined the responses of primary human monocytes to highly oxidized LDL molecules. Oxidized LDL readily induced secretion of chemokines MCP-1 (CCL2) and GRO-α (CXCL1) but unlike lipopolysaccharide (LPS), has limited capacity to induce a variety of other cytokines including tumor necrosis factor-α, IL-6, IL-1β and interferon-γ-induced protein-10 and also displayed a poor capacity to induce p-Akt or P-S6 signaling. Failure of oxidized LDL to induce IL-1β secretion was associated with limited induction of caspase-1 activation. Furthermore, despite finding evidence that oxidized LDL could enhance the expression of IL-15 and IL-15 receptor expression in monocytes, we found no evidence that it could confer IL-15 transpresentation capability to these cells. This observation contrasted with induction of IL-15 transpresentation in lipopolysaccharide-stimulated monocytes. Overall, our data suggest that highly oxidized LDL is a selective inducer of monocyte activation. Sterile inflammatory mediators, particularly those implicated in Toll-like receptor 4 signaling, may play a role in vascular pathology but the activities of these agents are not uniform.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  interleukin-15; monocytes; oxidized low-density lipoprotein

Mesh:

Substances:

Year:  2019        PMID: 31663113      PMCID: PMC6954695          DOI: 10.1111/imm.13142

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

1.  Oxidative Modification of LDL in the Pathogenesis of Atherosclerosis.

Authors:  Daniel Steinberg
Journal:  Am J Geriatr Cardiol       Date:  1993-10

2.  Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells.

Authors:  Matthew A Burchill; Christine A Goetz; Martin Prlic; Jennifer J O'Neil; Ian R Harmon; Steven J Bensinger; Laurence A Turka; Paul Brennan; Stephen C Jameson; Michael A Farrar
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

3.  Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation.

Authors:  H Y Huh; S F Pearce; L M Yesner; J L Schindler; R L Silverstein
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

4.  Oxidized Low-Density Lipoprotein Immune Complex Priming of the Nlrp3 Inflammasome Involves TLR and FcγR Cooperation and Is Dependent on CARD9.

Authors:  Jillian P Rhoads; John R Lukens; Ashley J Wilhelm; Jared L Moore; Yanice Mendez-Fernandez; Thirumala-Devi Kanneganti; Amy S Major
Journal:  J Immunol       Date:  2017-01-27       Impact factor: 5.422

5.  Activation of T lymphocytes in atherosclerotic plaques.

Authors:  Jean-Charles Grivel; Oxana Ivanova; Natalia Pinegina; Paul S Blank; Alexander Shpektor; Leonid B Margolis; Elena Vasilieva
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-09-29       Impact factor: 8.311

6.  Interleukin-15 expression in atherosclerotic plaques: an alternative pathway for T-cell activation in atherosclerosis?

Authors:  M A Houtkamp; A C van Der Wal; O J de Boer; C M van Der Loos; P A de Boer; A F Moorman; A E Becker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-07       Impact factor: 8.311

Review 7.  Cytokine Circuits in Cardiovascular Disease.

Authors:  Jesse W Williams; Li-Hao Huang; Gwendalyn J Randolph
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

8.  Plasma oxidized low-density lipoprotein levels and arterial stiffness in older adults: the health, aging, and body composition study.

Authors:  Tina E Brinkley; Barbara J Nicklas; Alka M Kanaya; Suzanne Satterfield; Edward G Lakatta; Eleanor M Simonsick; Kim Sutton-Tyrrell; Stephen B Kritchevsky
Journal:  Hypertension       Date:  2009-03-30       Impact factor: 10.190

9.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

Authors:  Rebecca C Coll; Avril A B Robertson; Jae Jin Chae; Sarah C Higgins; Raúl Muñoz-Planillo; Marco C Inserra; Irina Vetter; Lara S Dungan; Brian G Monks; Andrea Stutz; Daniel E Croker; Mark S Butler; Moritz Haneklaus; Caroline E Sutton; Gabriel Núñez; Eicke Latz; Daniel L Kastner; Kingston H G Mills; Seth L Masters; Kate Schroder; Matthew A Cooper; Luke A J O'Neill
Journal:  Nat Med       Date:  2015-02-16       Impact factor: 53.440

10.  Co-stimulation of PAFR and CD36 is required for oxLDL-induced human macrophages activation.

Authors:  Francisco J O Rios; Mariana M Koga; Matheus Ferracini; Sonia Jancar
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

View more
  2 in total

1.  Survey of In Vitro Model Systems for Investigation of Key Cellular Processes Associated with Atherosclerosis.

Authors:  Dipak P Ramji; Alaa Ismail; Jing Chen; Fahad Alradi; Sulaiman Al Alawi
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Novel Strategies to Combat CMV-Related Cardiovascular Disease.

Authors:  Elena Vasilieva; Sara Gianella; Michael L Freeman
Journal:  Pathog Immun       Date:  2020-09-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.